Journal of Chinese Pharmaceutical Sciences ›› 2020, Vol. 29 ›› Issue (9): 637-648.DOI: 10.5246/jcps.2020.09.059
• Original articles • Previous Articles Next Articles
Yi Zhou1, Junli Lai2, Feng Qiu1*, Jun Zhang2*
Received:
2020-05-14
Revised:
2020-07-06
Online:
2020-09-30
Published:
2020-08-16
Contact:
Tel.: +86-23-89012410, E-mail: qiufeng.cn@gmail.com; zjun2323@sina.cn
CLC Number:
Supporting:
Yi Zhou, Junli Lai, Feng Qiu, Jun Zhang. Development and validation of an HPLC-UV method for routine trough plasma concentration monitoring of imatinib in Chinese patients with gastrointestinal stromal tumor[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 637-648.
[1] Delbaldo, C.; Chatelut, E.; Ré, M.; Deroussent, A.; Séronie-Vivien, S.; Jambu, A.; Berthaud, P.; Le Cesne, A.; Blay, J.Y.; Vassal, G. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin. Cancer Res. 2006, 12, 6073-6078.
[2] Demetri, G.D.; Wang, Y.F.; Wehrle, E.; Racine, A.; Nikolova, Z.; Blanke, C.D.; Joensuu, H.; von Mehren, M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 2009, 27, 3141-3147.
[3] Tap, W.D.; Schwartz, G.K. That‟s the “GIST” of it: use of adjuvant imatinib after resection of a primary GI stromal tumor. J. Clin. Oncol. 2014, 32, 1543-1546.
[4] Widmer, N.; Bardin, C.; Chatelut, E.; Paci, A.; Beijnen, J.; Levêque, D.; Veal, G.; Astier, A. Review of therapeutic drug monitoring of anticancer drugs part two-Targeted therapies. Eur. J. Cancer. 2014, 50, 2020-2036.
[5] von Mehren, M.; Widmer, N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat. Rev. 2011, 37, 291-299.
[6] Bardin, C.; Veal, G.; Paci, A.; Chatelut, E.; Astier, A.; Levêque, D.; Widmer, N.; Beijnen, J. Therapeutic drug monitoring in cancer-Are we missing a trick? Eur. J. Cancer. 2014, 50, 2005-2009.
[7] Gotta, V.; Widmer, N.; Decosterd, L.A.; Chalandon, Y.; Heim, D.; Gregor, M.; Benz, R.; Leoncini-Franscini, L.; Baerlocher, G.M.; Duchosal, M.A.; Csajka, C.; Buclin, T. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother. Pharmacol. 2014, 74, 1307-1319.
[8] Judson, I. Therapeutic drug monitoring of imatinib: new data strengthen the case. Clin. Cancer Res. 2012, 18, 5517-5519.
[9] Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, iii21-iii26.
[10] Hochhaus, A.; Dreyling, M. Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. Ann. Oncol. 2008, 19, ii63-ii64.
[11] von Mehren, M.; Randall, R.L.; Benjamin, R.S.; Boles, S.; Bui, M.M.; Casper, E.S.; Conrad, E.U. III, DeLaney, T.F.; Ganjoo, K.N.; George, S.; Gonzalez, R.J.; Heslin, M.J.; Kane, J.M. III, Mayerson, J.; McGarry, S.V.; Meyer, C.; O‟Donnell, R.J.; Pappo, A.S.; Paz, I.B.; Pfeifer, J.D.; Riedel, R.F.; Schuetze, S.; Schupak, K.D.; Schwartz, H.S.; van Tine, B.A.; Wayne, J.D.; Bergman, M.A.; Sundar, H. Gastrointestinal stromal tumors. J. Natl. Compr. Cancer Netw. 2014, 12, 853-862.
[12] Yoon, S.; Ryu, M.H.; Yoo, C.; Beck, M.Y.; Ryoo, B.Y.; Kang, Y.K. Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients. J. Korean Med. Sci. 2013, 28, 1248-1252.
[13] Lankheet, N.A.G.; Knapen, L.M.; Schellens, J.H.M.; Beijnen, J.H.; Steeghs, N.; Huitema, A.D.R. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther. Drug Monit. 2014, 36, 326-334.
[14] Miura, M.; Takahashi, N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods. Drug Metab. Pharmacokinet. 2016, 31, 12-20.
[15] Davies, A.; Hayes, A.K.; Knight, K.; Watmough, S.J.; Pirmohamed, M.; Clark, R.E. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk. Res. 2010, 34, 702-707.
[16] Widmer, N.; Béguin, A.; Rochat, B.; Buclin, T.; Kovacsovics, T.; Duchosal, M.A.; Leyvraz, S.; Rosselet, A.; Biollaz, J.; Decosterd, L.A. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J. Chromatogr. B. 2004, 803, 285-292.
[17] Bende, G.; Kollipara, S.; Movva, S.; Moorthy, G.; Saha, R. Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. J. Chromatogr. Sci. 2010, 48, 334-341.
[18] Awidi, A.; Salem, I.I.; Najib, N.; Mefleh, R.; Tarawneh, B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: Methods‟ comparison. Leuk. Res. 2010, 34, 714-717.
[19] Miura, M.; Takahashi, N.; Sawada, K.I. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. Sci. 2011, 49, 412-415.
[20] Golabchifar, A.A.; Rouini, M.R.; Shafaghi, B.; Rezaee, S.; Foroumadi, A.; Khoshayand, M.R. Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design. Talanta. 2011, 85, 2320-2329.
[21] Pirro, E.; de Francia, S.; de Martino, F.; Racca, S.; di Carlo, F.; Fava, C.; Ulisciani, S.; Rege Cambrin, G.; Saglio, G. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J. Chromatogr. Sci. 2011, 49, 753-757.
[22] Miura, M.; Takahashi, N.; Sawada, K.I. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. Sci. 2011, 49, 412-415.
[23] Tan, K.L.; Ankathil, R.; Gan, S.H. Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. J. Chromatogr. B. 2011, 879, 3583-3591.
[24] Alkharfy, K.M.; Khan, R.M.A.; Al-Asmari, M.; Alhadeyah, B.H.; Ahmad, A. Quantitative determination of imatinib stability under various stress conditions. J. Pharm. Bioallied Sci. 2013, 5, 49-52.
[25] Birch, M.; Morgan, P.E.; Handley, S.; Ho, A.; Ireland, R.; Flanagan, R.J. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed. Chromatogr. 2013, 27, 335-342.
[26] Kaza, M.; Piorkowska, E.; Filist, M.; Rudzki, P.J. Hplc-uv assay of imatinib in human plasma optimized for bioequivalence studies. Acta Pol. Pharm. 2016, 73, 1495-1503.
[27] Velpandian, T.; Mathur, R.; Agarwal, N.K.; Arora, B.; Kumar, L.; Gupta, S.K. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J. Chromatogr. B. 2004, 804, 431-434.
[28] Schleyer, E.; Pursche, S.; Köhne, C.H.; Schuler, U.; Renner, U.; Gschaidmeier, H.; Freiberg-Richter, J.; Leopold, T.; Jenke, A.; Bonin, M.; Bergemann, T.; le Coutre, P.; Gruner, M.; Bornhäuser, M.; Ottmann, O.G.; Ehninger, G. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J. Chromatogr. B. 2004, 799, 23-36.
[29] Roth, O.; Spreux-Varoquaux, O.; Bouchet, S.; Rousselot, P.; Castaigne, S.; Rigaudeau, S.; Raggueneau, V.; Therond, P.; Devillier, P.; Molimard, M.; Maneglier, B. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clin. Chimica Acta. 2010, 411, 140-146.
[30] Bioanalytical Method Validation. Guidance for Industry. U.S. Food and Drug Administration. 2018, 1-41. https://www.fda.gov/media/70858/download.
[31] Guideline on bioanalytical method validation. Eur. Med. Agency. 2012, 1-23. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
[32] Wang, Y.F.; Chia, Y.L.; Nedelman, J.; Schran, H.; Mahon, F.; Molimard, M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther. Drug Monit. 2009, 31, 579-584.
[33] Ramazani, F.; Chen, W.; van Nostrum, C.F.; Storm, G.; Kiessling, F.; Lammers, T.; Hennink, W.E.; Kok, R.J. Formulation and characterization of microspheres loaded with imatinib for sustained delivery. Int. J. Pharm. 2015, 482, 123-130.
[34] Yadav, M.; Shrivastav, P.S. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis. 2011, 3, 1007-1024.
[35] Teng, J.F.T.; Mabasa, V.H.; Ensom, M.H.H. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther. Drug Monit. 2012, 34, 85-97. |
[1] | Yanqing Zhou, Yonghong Liu, Yanting Li, Yanru Tao, Jin Li, Xinhui Jiang. Determination of chlorogenic acid and rutin in extractive solution of ficus virens leaves by HPLC-PDA [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(1): 45-51. |
[2] | Xiangfei Jin, Minyue Cheng, Sihui Zhong, Yungen Xu, Weiyang Shen. Identification of unknown impurities in triamcinolone acetonide palmitate [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(4): 270-278. |
[3] | Miao Li, Xiaoyan Kong, Shumei Wang. Risk factors for delayed methotrexate elimination in pediatric patients with hematological malignancies: a retrospective analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 746-754. |
[4] | Yi Zhou, Xingye Wu, Juan Li, Wei Cheng, Xiaosong Li, Yifan Shen, Jun Zhang. Clinical and economic benefits of a pharmacist in a multidisciplinary team for Chinese outpatients with gastrointestinal stromal tumors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(7): 598-605. |
[5] | Xin Dong, Hong Wang, Feixiang Ma, Jianping Gao, Shizhong Chen, Peifeng Xue. A strategy for structure-activity relationship study on antioxidants in Echinops latifolius Tausch extracts by online HPLC-radical scavenging detection coupled with ESI-IT-TOF-MSn [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 267-279. |
[6] | Zijuan Lu, Yan Jia, Jie Xing, Shuxian Xiao, Yulong Wang, Wenjie Qin, Xuemei Qin, Zhenyu Li. Quality evaluation of Farfarae Flos by ITS/ITS2 and HPLC fingerprint analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 58-68. |
[7] | Shaojing Liu, Bei Qin, Hongfang Han, Li Li, Lili Yu, Xiaojing Xu. Preparative separation of high-purity troxerutin and related substances from mother liquor of troxerutin by silica gel column chromatography and semi-preparative liquid chromatography [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(7): 487-493. |
[8] | Chaohui Wu, Huifen Lin, Weiwei Lin, Yiwei Liu, Xiang You, Cuihong Lin, Rongfang Lin, Dayong Zeng, Pinfang Huang. A prospective cohort study on the relationship between vancomycin steady-state trough concentration and efficacy and safety in Chinese adults [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 341-354. |
[9] | Hongshuai Yang, Qiuyi Liu, Weidong Yin, Manjiang Xie, Xiang Ji, Shuangyu Shao, Hong Liang, Pengfei Tu, Qingying Zhang. Identification and discrimination of Ziziphi Spinosae Semen and Ziziphi Mauritianae Semen based on HPLC fingerprint analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 252-259. |
[10] | Fei Yu, Wenli Zhou, Jiayi Kan, Can Peng. Comparison of dissolution profile characteristics of 11 berberine hydrochloride tablet brands in different dissolution media [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 102-112. |
[11] | Weijuan Jia, Shizhong Chen, Jianhua Sun, Zongli Bai, Yazhuo Huang, Yuankuan Zhang, Hong Wang. Quality evaluation of Polyporus umbellatus based on HPLC specific chromatogram and fingerprint analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(12): 896-907. |
[12] | Lulu Xu, Zhanpeng Shang, Yue Chai, Yang Zhang, Rong Yu, Min Ye, Xue Qiao. Detection of minor constituents in TongMai Granules using NP×RP off-line two-dimensional liquid chromatography coupled with orbitrap mass spectrometry [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(11): 793-803. |
[13] | Xiuwei Yang, Youbo Zhang, Wei Xu. Determination and pharmacokinetic study of p-hydroxyphenethyl anisate following intravenous and oral administration in rats by RP-HPLC method [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(11): 804-812. |
[14] | Wen Zhang, Kangfei Duan, Mingying Shang, Meng Guan, Deyun Li, Zongli Bai, Zhiyong Le, Shaoqing Cai. Effects of harvesting time and processing on the contents of five alkaloids in the herbaceous stems of Ephedra sinica [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 339-347. |
[15] | Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 146
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 335
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||